Treats serious bacterial infections caused by susceptible strains of the designated…. ANDA 65013, held by Xgen Pharms. Tobramycin Sulfate.
As of Nov 16, 2026, ANDA 65013 (Tobramycin Sulfate), held by Xgen Pharms, was first approved by FDA on Aug 17, 2001, with 9 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: - Septicemia in the neonate, child, and adult caused by P. aeruginosa, E. coli, and Klebsiella sp. - Lower respiratory tract infections caused by P. aeruginosa, Klebsiella sp, Enterobacter sp, Serratia sp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains). - Serious central-nervous-system infections (meningitis) caused by susceptible organisms. - Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella sp, and Enterobacter sp.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 17, 2001 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tobramycin SulfateEQ 1.2GM BASE/VIAL · injectable;injection | Tobramycin Sulfate | Rx |
| Aug 29, 2023 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 10, 2023 | Supplement 16Labeling · Standard review | Approved | None posted |
| Oct 7, 2013 | Supplement 10Manufacturing | Approved | None posted |
| Aug 16, 2013 | Supplement 12Labeling · Standard review | Approved | None posted |
| Nov 9, 2012 | Supplement 11Labeling · Standard review | Approved | None posted |
| Oct 31, 2012 | Supplement 9Labeling | Approved | None posted |
| Jan 17, 2012 | Supplement 7Labeling | Approved | |
| Oct 18, 2010 | Supplement 8Labeling | Approved | None posted |
| Dec 9, 2002 | Supplement 2Manufacturing | Approved | None posted |
| Aug 17, 2001 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters